PharmaCyte Biotech (PMCB) Accounts Payables (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Accounts Payables of $271102.0 for Q2 2026, down 32.09% year-over-year from $399204.0 in Q2 2025, and down 77.41% quarter-over-quarter from $1.2 million in Q1 2026.
PharmaCyte Biotech (PMCB) Accounts Payables (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Accounts Payables for 16 consecutive years, with $271102.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Accounts Payables fell 32.09% year-over-year to $271102.0; the TTM figure through Apr 2026 stood at $271102.0 (down 32.09% YoY), while the FY2026 annual figure was $271102.0, down 32.09% from the prior year.
- Accounts Payables eased to $271102.0 in Q2 2026 per PMCB's latest filing, from $1.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $1.2 million in Q1 2026 and bottomed at $92861.0 in Q1 2022.
- Historically, Accounts Payables has averaged $505603.4 across 5 years, with a median of $474703.5 in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 85.35% — and 2024, when it surged 473.12%.
- PharmaCyte Biotech's Accounts Payables stood at $861276.0 in 2022, then slumped by 85.35% to $126163.0 in 2023, then soared by 176.31% to $348595.0 in 2024, then surged by 192.99% to $1.0 million in 2025, then slumped by 73.46% to $271102.0 in 2026.
- Business Quant data shows PMCB's Accounts Payables at $271102.0 in Q2 2026, $1.2 million in Q1 2026, and $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 271,102.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 271,102.00 |
| Jan 31, 2026 | 1.20 Mn |
| Oct 31, 2025 | 1.02 Mn |
| Jul 31, 2025 | 465,209.00 |
| Apr 30, 2025 | 399,204.00 |
| Jan 31, 2025 | 484,948.00 |
| Oct 31, 2024 | 348,595.00 |
| Jul 31, 2024 | 553,952.00 |
| Apr 30, 2024 | 735,199.00 |
| Jan 31, 2024 | 484,198.00 |
| Oct 31, 2023 | 126,163.00 |
| Jul 31, 2023 | 718,130.00 |
| Apr 30, 2023 | 128,281.00 |
| Jan 31, 2023 | 445,935.00 |
| Oct 31, 2022 | 861,276.00 |
| Jul 31, 2022 | 559,026.00 |
| Apr 30, 2022 | 205,361.00 |
| Jan 31, 2022 | 92,861.00 |
| Oct 31, 2021 | 157,039.00 |
| Jul 31, 2021 | 394,775.00 |